Announced Tue, 19 May · 23:12 IST

The Board of Directors of the Company approved the re-appointment of Mr. Rajiv Maliwal (DIN: 00869035) as a Non-Executive Independent Director of the Company for a second term of 5 consecutive ....

Management Changes View source PDF

HCG · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-2.7%1-day move
₹649.50
prior close
₹632.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+2.3+3.4+3.4+2.9-2.7+0.9+1.3+1.0+1.6-0.5-3.5-5.4+0.9
Up moveDown movePending
AI summary

HCG's Board approved multiple leadership changes on May 19, 2026. Mr. Rajiv Maliwal was re-appointed as Non-Executive Independent Director for a second 5-year term starting May 25, 2026, subject to shareholder approval. The company also appointed Mr. Sanjeev Kumar (formerly Group CFO at InterGlobe Enterprises and Medanta) as its new Chief Financial Officer and Key Managerial Personnel from May 25, 2026. Consequently, Dr. Manish Mattoo (CEO) will cease to hold the additional charge of Interim CFO from the same date. Additionally, Mr. Ravi Gothwal was appointed as AVP - Investor Relations (Senior Management Personnel) effective May 19, 2026, and Mr. Vijay S. Shanbhag was re-appointed as Internal Auditor for one year from May 30, 2026.

Likely market impact

The appointment of a dedicated, experienced CFO like Sanjeev Kumar (who led Medanta's IPO) signals strengthened financial leadership. The continuation of Rajiv Maliwal as Independent Director provides board stability and continuity of governance.